Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Contact information



Primary contact

Prof MK Parmar


Contact details

MRC Clinical Trials Unit
222 Euston Road
United Kingdom

Additional identifiers

EudraCT number number


Protocol/serial number

G9805643 (PR07)

Study information

Scientific title

A randomised clinical trial of hormones plus radiotherapy vs hormone therapy alone in non-metastatic prostate cancer


Study hypothesis

To evaluate any possible benefit from the addition of external beam radiation therapy to the treatment of patients with non-metastatic prostate cancer who have not had a radical prostatectomy and are receiving hormonal therapy.

More details can be found at:

Ethics approval

Not provided at time of registration.

Study design

Randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Prostate cancer


All patients will receive hormonal manipulation.
Patients are randomised to receive:
1. Additional radiotherapy (65-69Gy/35-37f)
2. No additional radiotherapy

Intervention type



Drug names

Primary outcome measure

Overall survival

Secondary outcome measures

1. Time to disease progression
2. Symptomatic local control measured by the rates of surgical interventions necessary for symptomatic local disease (I.e. the combined incidences of TURPs, stent insertions, nephrostomies and colostomies)
3. Quality of Life measured by the FACT-P questionnaire

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Histological diagnosis of adenocarcinoma of the prostate within 6 months of randomisation
2. Either (a) clinical stage T3 or T4, NO or NX, MO or (b) clinical stage T2, NO or NX, MO with Prostate-Specific Antigen (PSA) greater than 40 or (c) clinical stage T2, NO or NX, MO with PSA greater than 20 and Gleason sum score greater than or equal to 8
3. The patient must have a bone scan (with X-rays of any areas of abnormal uptake) reported as being free of evidence of bony metastases within 16 weeks prior to randomisation (if not already on hormones) or 16 weeks prior to the start of hormones (if on hormones already)
4. No previous treatment for prostate cancer apart from transurethral resection. However, the patient may have received prior hormone therapy during the 12 weeks prior to randomisation, provided that (a) a negative bone scan was demonstrated, preferably within the 16 weeks prior to starting hormone therapy but certainly within 2 weeks after starting hormone therapy and (b) baseline PSA within 4 weeks prior to hormone therapy is available
5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
6. Patients must be less than 80 years old
7. Written informed consent

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. A history of previous or concurrent malignancy other than non-melanomatous skin cancer within 5 years of diagnosis of the prostatic cancer.
2. The presence of small-cell or transitional-cell carcinoma in the biopsy specimen.
3. Any contraindication to pelvic radiotherapy (e.g. inflammatory bowel disease).
4. Any serious non-malignant disease resulting in a life expectancy of less than 5 years.

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom, United States of America

Trial participating centre

MRC Clinical Trials Unit
United Kingdom

Sponsor information


Medical Research Council (MRC) Clinical Trials Unit - Cancer Division (UK)

Sponsor details

222 Euston Road
United Kingdom

Sponsor type

Research council



Funder type

Research council

Funder name

Medical Research Council (UK)

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

National government


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

1. 2000 protocol in:
2. 2005 appraisal in:
3. 2012 results in:
4. 2015 results in:

Publication citations

  1. Appraisal

    Mason M, Warde P, Sydes M, Cowan R, James N, Kirkbride P, Langley R, Latham J, Moynihan C, Anderson J, Millet J, Nutall J, Moffat L, Parulekar W, Parmar M, , , Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study., Clin Oncol (R Coll Radiol), 2005, 17, 4, 217-218.

  2. Results

    Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, , Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial., Lancet, 2011, 378, 9809, 2104-2111, doi: 10.1016/S0140-6736(11)61095-7.

  3. Protocol

    Mason MD, Brewster S, Moffat LE, Kirkbride P, Cowan RA, Malone P, Sydes M, Parmar MK, Randomized trials in early prostate cancer. II: hormone therapy and radiotherapy for locally advanced disease: a question is still unanswered. MRC PR07 Trial Management Group., Clin Oncol (R Coll Radiol), 2000, 12, 4, 215-216.

  4. Results

    Brundage M, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A, Kirkbride P, Parliament M, Moynihan C, Bahary JP, Parmar MK, Sanders K, Chen BE, Mason MD, Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial, J Clin Oncol, 2015, 33, 19, 2151-2157, doi: 10.1200/JCO.2014.57.8724.

Additional files

Editorial Notes

18/10/2018: Cancer Research UK lay results summary link added to Results (plain English)